SEC Filings TLDR Banner

Stop wasting hours on dense SEC filings. Get AI-powered summaries of any SEC Filings in seconds. Understand key insights and risks, fast.

Currently we only process Form 8-K, 6-K, 3, 4, 144, Schedule 13D and Schedule 13G. We will support more forms in the future.

Filter by Form Type:
All346-K8-K10-Q144Schedule 13GSchedule 13G/ASchedule 13DSchedule 13D/A
Industry:Biotechnologyβœ•
Previous Page1617181920212223Next Page
2026-08-12TVTXSCHEDULE 13GBank of America Corp Reports New 5.8% Passive Stake in Travere Therapeutics (TVTX)MEDIUM
Bank of America Corporation has filed a Schedule 13G reporting a new 5.8% passive ownership stake in Travere Therapeutics, Inc. (TVTX). As of June 30, 2026, the financial institution beneficially owns 5,439,155 shares of Common Stock. This filing represents a significant increase from a previous 0.0% position, crossing...
Mid CapBiotechnologyownership +5.80%
2026-08-12CYBNSCHEDULE 13GAdage Capital Management Reports New 5.29% Stake in Cybin Inc.MEDIUM
Adage Capital Management, L.P., along with Robert Atchinson and Phillip Gross, has filed a Schedule 13G reporting a new 5.29% ownership stake in Cybin Inc. (CYBN). As of the event date of June 30, 2026, the reporting persons beneficially own 3,289,250 common shares. This total includes 229,250 common shares issuable up...
Biotechnologyownership +5.29%
2026-08-12CABASCHEDULE 13GNorges Bank Reports New 5.38% Passive Stake in Cabaletta Bio, Inc. (CABA)MEDIUM
On August 12, 2026, Norges Bank filed a Schedule 13G with the SEC, reporting a new ownership stake in Cabaletta Bio, Inc. (CABA). As of the event date on June 30, 2026, the central bank of Norway holds 8,775,653 shares of Common Stock, representing 5.382% of the company. This filing marks Norges Bank as a significant i...
Small CapBiotechnologyownership +5.38%
Previous Page1617181920212223Next Page